Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

Authors:
  • TGThe GlaxoSmithKline Herpes Vaccine Study Group
    The GlaxoSmithKline Herpes Vaccine Study Group

Abstract
Background. Two previous trials have suggested that a herpes simplex virus (HSV) type 2 glycoprotein D (gD) vaccine combined with the adjuvants alum

This publication has 9 references indexed in Scilit: